When a company such as Bolt Biotherapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the BOLT split history from start to finish, an original position size of 1000 shares would have turned into 1500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bolt Biotherapeutics shares, starting with a $10,000 purchase of BOLT, presented on a split-history-adjusted basis factoring in the complete BOLT split history.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer.. Co.'s proprietary Boltbody™ ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. Co.'s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gastroesophageal cancer. Co.'s second program, BDC-3042, is an agonist antibody targeting Dectin-2, an innate immune receptor found on the surface of macrophages. According to our BOLT split history records, Bolt Biotherapeutics has had 1 split.

BOLT Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved